Charles Fletcher, PA
Medical · Wichita, KSNPI 1639151020
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 25.1% of the total.
Across 83 payments — averaging $36.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$768
- Boehringer Ingelheim$612
- Merck$353
- Daiichi Sankyo Inc.$262
- Johnson & Johnson$238
- Ascendis Pharma Endocrinology Inc$200
- plus $628 from 14 others
What the payments were for
- Food & beverage$3,03999%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $768 |
| Boehringer Ingelheim | 16 | $612 |
| Merck | 23 | $353 |
| Daiichi Sankyo Inc. | 4 | $262 |
| Johnson & Johnson | 2 | $238 |
| Ascendis Pharma Endocrinology Inc | 2 | $200 |
| Amgen | 5 | $179 |
| Lilly USA, LLC | 5 | $129 |
| Arbor Pharmaceuticals, Inc. | 3 | $54 |
| Angiodynamics, Inc. | 1 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $37 |
| Pfizer | 2 | $31 |
| AbbVie | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,061 in reported general payments places this provider in the 75th percentile of 205 medical providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $147,003 |
| JardianceEmpagliflozin | 115 | $82,757 |
| MounjaroTirzepatide | 31 | $38,479 |
| JanuviaSitagliptin Phosphate | 14 | $16,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,127 |
| XareltoRivaroxaban | 12 | $9,769 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,878 |
| Repatha SureclickEvolocumab | 12 | $6,578 |
| CorlanorIvabradine Hcl | 11 | $6,450 |
| SavellaMilnacipran Hcl | 13 | $6,225 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,762 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,165 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 74 | $1,874 |
| Tolterodine Tartrate | 12 | $1,421 |
| Buspirone Hcl | 123 | $1,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $768 | $147,003119 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $612 | $89,635129 claims |
| Lilly USA, LLCMounjaro | $129 | $38,47931 claims |
| MerckJanuvia | $353 | $16,18514 claims |
| Johnson & JohnsonXarelto | $238 | $9,76912 claims |
| AbbVieSavella, Synthroid | $22 | $7,54732 claims |
| AmgenCorlanor | $179 | $6,45011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 205 medical providers in Kansas.
Other medical in Wichita
- Richard AllenbachWichita$70K
- Kathryn WelchWichita$32K
- Jason MengesWichita$15K
- Trang BrownleeWichita$11K
- Susan GeorgeWichita$10K
- Andrew OsbeckWichita$9K
- Lisa HarrisWichita$8K
- Christiane YourdonWichita$6K
- Kristen OchsnerWichita$5K
- Kristen WolfWichita$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.